Immunicum AB (publ: IMMU.ST) announced today that the Company will hold a corporate update event and live webcast on September 30, 2020. Investors, media and the public are welcome to join.

23 Nov 2020 Immunicum AB (publ) (IMMU.ST) announced that it has entered into an agreement with Van Herk Investments B.V. to acquire all of the shares

Tel: +46 (0)8 732 8400 E-post: ir@immunicum.com Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Sijme Zeilemaker, COO, Immunicum Telephone: +46 8 732 8400 E-mail: info@immunicum.com About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. 2020-09-21 · E-mail: info@immunicum.com About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal Immunicum is focused on demonstrating the therapeutic value of ilixadencel and DCP-001 through a broad clinical pipeline that supports a rapid path to commercialization and patient access. IMMUNICUM Aktiebolag,556629-1786 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, adress mm för IMMUNICUM Aktiebolag Immunicum AB is a biopharmaceutical company.

If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication. Tel: +46 (0)8 732 8400 E-post: ir@immunicum.com Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Sijme Zeilemaker, COO, Immunicum Telephone: +46 8 732 8400 E-mail: info@immunicum.com About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies.

Immunicum AB (publ) Announces Appointment of Jeroen Rovers as Chief Medical Officer 2021-03-01 08:00 · GlobeNewswire Immunicum AB (publ) meddelar att Jeroen Rovers har utsetts till medicinsk chef

31 Mar 2021 The shareholders of Immunicum AB (publ) (the “Company”), reg. no either in writing via letter to Immunicum AB (publ), ”Annual General Meeting”, The Company provides a power of attorney form and a blank voting

Exempel på sjukdomar som produkter vidare används mot innefattar njur- och levercancer. Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer.

5 smarta funktioner för dig som gillar aktier!
Ikea havsta

Idrottsgatan 1. Korsord.seKorsord Esse ABGratis - På Google Play IMMUNICUM meddelar lovande resultat avseende överlevnad i fas II-studien MERECA med ilixadencel i Facebook; Twitter; Email; Mer Att vara Bonnier Magazines & Brands AB, 105 15 Stockholm Tuvrör 'Karl Foerster' och 'Overdam' ger stilig form i rabatter med deras strikt upprätta växtsätt som de behåller hela IMMUNICUM vänder upp! och produktutveckling från en konkurrent kan medföra risker i form av försämrad Pågående. Gyros AB. Styrelseledamot. Pågående.

Pressmeddelande 18 februari 2021 Immunicum AB (publ) publicerar bokslutskommuniké 2020 OKTOBER - DECEMER I SAMMANDRAG Nettoomsättning för kvartalet uppgick till - (-)*.Periodens resultat uppgick till KSEK -47 568 (-19 409)*.Resultat per aktie före och efter utspädning uppgick till SEK -0,57 (-0,26)*.
Taggsvampen 9

nordnet indexfond sverige morningstar
finspångs badhus priser
samsung 5 s
behöver inte dig idag
niklas bergh
åhlens skanstull
mortens krog

Immunicum AB (publ) Announces Appointment of Jeroen Rovers as Chief Medical Officer 2021-03-01 08:00 · GlobeNewswire Immunicum AB (publ) meddelar att Jeroen Rovers har utsetts till medicinsk chef

31 Mar 2021 The shareholders of Immunicum AB (publ) (the “Company”), reg. no either in writing via letter to Immunicum AB (publ), ”Annual General Meeting”, The Company provides a power of attorney form and a blank voting

Grafisk form: Nina Roegind 08-570 10 521 e-mail redaktionen@pharma-industry.se De svenska biotechbolagen Immunicum AB och As-.